 | • レポートコード：MRC2303K051 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の調査レポートでは、世界のグラム陽性菌感染症市場規模が、予測期間中、CAGR 8％で増大すると予測されています。本レポートでは、グラム陽性菌感染症の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、薬剤種類別（β-ラクタム系抗菌剤、フルオロキノロン系抗菌薬、ペニシリン、セファロスポリン類、その他）分析、疾患別（肺炎、敗血症、咽頭炎、メチシリン耐性黄色ブドウ球菌（MRSA）感染症、その他）分析、流通チャネル別（病院内薬局、小売薬局、オンライン薬局）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などについて調査・分析などの項目を掲載しています。並び、こちらのレポートには、GlaxoSmithKline Plc、Johnson & Johnson Inc.、Merck & Co. Inc.、Pfizer Inc.、AstraZeneca、Cumberland Pharmaceuticals、Novartis AG、Sanofi SA、Sun Pharmaceutical Industries Ltd.、Cipla Ltd.、Bayer AG、Bristol-Myers Squibb Companyなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のグラム陽性菌感染症市場規模：薬剤種類別 - β-ラクタム系抗菌剤の市場規模 - フルオロキノロン系抗菌薬の市場規模 - ペニシリンの市場規模 - セファロスポリン類の市場規模 - その他グラム陽性菌感染症の市場規模 ・世界のグラム陽性菌感染症市場規模：疾患別 - 肺炎における市場規模 - 敗血症における市場規模 - 咽頭炎における市場規模 - メチシリン耐性黄色ブドウ球菌（MRSA）感染症における市場規模 - その他疾患における市場規模 ・世界のグラム陽性菌感染症市場規模：流通チャネル別 - 病院内薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 ・世界のグラム陽性菌感染症市場規模：地域別 - 北米のグラム陽性菌感染症市場規模 アメリカのグラム陽性菌感染症市場規模 カナダのグラム陽性菌感染症市場規模 メキシコのグラム陽性菌感染症市場規模 … - ヨーロッパのグラム陽性菌感染症市場規模 ドイツのグラム陽性菌感染症市場規模 イギリスのグラム陽性菌感染症市場規模 フランスのグラム陽性菌感染症市場規模 … - アジア太平洋のグラム陽性菌感染症市場規模 中国のグラム陽性菌感染症市場規模 日本のグラム陽性菌感染症市場規模 インドのグラム陽性菌感染症市場規模 … - 南米/中東のグラム陽性菌感染症市場規模 南アフリカのグラム陽性菌感染症市場規模 ブラジルのグラム陽性菌感染症市場規模 アルゼンチンのグラム陽性菌感染症市場規模 … ・競争状況 ・市場機会・将来動向 |
The gram-positive bacterial infections market is expected to register a CAGR of 8.0% over the forecast period.
The outbreak of COVID-19 had impacted the global healthcare system and significantly impacted the gram-positive bacterial infections market. The increase in COVID-19 cases led to an increase in lung complications such as pneumonia and that surged the demand for drugs against gram-positive bacteria. For instance, an article published by John Hopkins Medicine, in February 2022, reported that pneumonia, caused by COVID-19 filled the lungs with fluid, leading to breathing difficulties. The article also reported an increase in pneumonia cases during the pandemic. Thus, COVID-19 led to an increasing demand for drugs against gram-positive bacteria. However, it was anticipated that with a decrease in COVID-19 cases, the demand for these drugs may get reduced as compared to the initial pandemic times. Still, due to the presence of other gram-positive bacterial infections, the demand for drugs against gram-positive bacteria will keep on increasing. The market is expected to witness significant growth over the forecast period.
The factors that are driving this market are the rising prevalence of gram-positive bacterial infections and an increasing number of drug approvals. For instance, an article published by Merck Manual in September 2022, reported that gram-positive bacteria cause severe infections and in some cases, they may be fatal. The article also said that anthrax is a potentially fatal infection caused by gram-positive bacteria. Thus, the high burden of gram-positive bacterial infections is increasing the demand for drugs to treat them.
Similarly, in May 2022, UNICEF reported that globally, there are over 1,400 cases of pneumonia per 100,000 children, or 1 case per 71 children every year, with the greatest incidence occurring in South Asia (2,500 cases per 100,000 children) and West and Central Africa (1,620 cases per 100,000 children). Thus, such a high incidence of pneumonia (gram-positive bacteria infections) is increasing the demand for drugs against them, thereby driving the growth of the studied market.
Furthermore, to overcome this rising infection caused by gram-positive bacteria, many government authorities like the US FDA and Health Canada, etc are taking initiative and approving many antibiotics to treat this bacterial infection. For instance, in 2021, the US FDA approved 50 new molecules to treat rising bacterial infections. These new molecules were approved by the government to overcome and prevent the spread of rising gram-positive bacterial infections. Thus, the introduction of new molecules that may treat a wide range of gram-positive bacterial infections is expected to drive the growth of the studied market.
Therefore, due to the rising prevalence of gram-positive bacterial infections and increasing number of drug approvals, the market is expected to witness significant growth over the forecast period. However, due to antibiotic resistance, the growth of the studied market may get slow which may affect its growth over the forecast period.
Gram Positive Bacterial Infections Market Trends
Cephalosporins Segment is Expected to Witness Significant Growth over the Forecast Period.
Cephalosporins are beta-lactam antibiotics that inhibit the synthesis of peptidoglycan, present in the cell wall of bacteria. Cephalosporins are indicated for the treatment of infections caused by gram-positive bacteria in certain circumstances. These include selected patients with endocarditis, osteomyelitis, septic arthritis, and cellulitis. The burden of infectious diseases across the world is increasing, which is resulting in the rising focus on the diagnosis and treatment of the same, and cephalosporin is considered a point of treatment for most of these infections, thus driving the demand for cephalosporin.
The growing global prevalence of gram-positive bacteria infections such as those caused by Streptococcus and Staphylococcus is constantly increasing the demand for third-generation cephalosporins for its treatment. For instance, an article published by NCBI, in September 2022, reported that third-generation cephalosporins are medications used in the management and treatment of infections caused by gram-positive organisms. The article also quoted the effectiveness of cephalosporins in the treatment of anthrax. Thus, the widespread use of cephalosporins for the treatment of various gram-positive bacterial infections is driving this segment.
Furthermore, the increased number of strategic partnerships is leading to the development of new products and also providing better treatment options thereby opening new market growth opportunities. For instance, in July 2022, Mast launched the Ceftobiprole 5µg to the MASTDISCS Antimicrobial Susceptibility Test range. Ceftobiprole (Zevtera/Mabelio) is a broad-spectrum 5th generation Cephalosporin indicated in several countries in Europe for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP). Ceftobiprole is an effective option for targeted empirical therapy due to its broad spectrum of activity, its potent activity against methicillin-resistant Staphylococcus aureus (MRSA), and its good safety profile. Moreover, the rising gram-positive bacterial infections, the easy availability of cephalosporins delivered through retail pharmacies, and the surge in the number of retail pharmacies in developed countries create opportunities for the increased use of cephalosporins, thereby driving the growth of this segment.
Thus, due to the rising avialability of cephalosporins, its wide application for treatment of various infectious diseases and the new product launches the segment is expected to witness significant growth over the forecast period, thereby propelling the growth of the studied market.
North America is Expected to Witness a Significant Growth Over the Forecast Period.
North American region shares are expected to witness significant growth over the forecast period, due to the rising prevalence of infectious diseases, increasing healthcare expenditure, large population base, and rise in funding for the development of antibiotics.
The increased infections caused by gram-positive bacteria are increasing the demand for drugs against gram-positive bacteria, thereby driving the growth of the studied market. For instance, news published by Cattle Site, in August 2022, reported that high rate of anthrax infections among farmers in Canada in the year 2021. Also, the Canadian Antimicrobial Resistance Surveillance System Report 2021, stated the high prevalence of gram-positive bacteria infections among the Canadian population during the COVID-19 pandemic.
Similarly, an article published in the Mexican journal, Revista Medica del Instituto Mexicano del Seguro Social in July 2022 reported that S. aureus, E Coli, Klebsiella, Candida, and Pseudomonas remain the main causative agents of infection in most of the bacterial infections in the country. Thus, increasing bacterial infections caused by various bacterial species are driving the demand for antibiotics for treatment, driving the growth of antibiotics in the region.
Furthermore, strategic activities adopted by the market players such as product launches, mergers, and acquisitions are expected to expand the market. For instance, in March 2021, Shionogi & Co., Ltd’s Cefiderocol completed three global trials in patients with complicated urinary tract infections, a Phase 3 trial in patients with carbapenem-resistant and a Phase 3 trial in patients with nosocomial pneumonia and has been approved by the US FDA. Thus, such a new launch of new drugs to treat rising bacterial infections is driving the market in the region.
Thus, due to the rising prevalence of infectious diseases, increasing healthcare expenditure, large population base, and rise in funding the region is expected to witness significant growth over the forecast period, thereby fueling the growth of the market.
Gram Positive Bacterial Infections Market Competitor Analysis
The gram-positive bacterial infections market is competitive and consists of many players operating globally and regionally. However, the large layers of the industry are vertically integrated. Some of the companies which are currently dominating the market are GlaxoSmithKline Plc, Johnson & Johnson Inc., Merck & Co. Inc., Pfizer Inc., AstraZeneca, Cumberland Pharmaceuticals, Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Bayer AG, and Bristol-Myers Squibb Company.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Gram-positive Bacterial Infections
4.2.2 Increasing Number of Drug Approvals
4.3 Market Restraints
4.3.1 Antibiotic Resistance
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Drug Type
5.1.1 Beta-Lactam Antimicrobials
5.1.2 Fluoroquinolones
5.1.3 Penicillin
5.1.4 Cephalosporins
5.1.5 RNA Immunoprecipitation (RIP)
5.1.6 Vaccine
5.1.7 Others Drugs
5.2 By Disease
5.2.1 Pneumonia
5.2.2 Sepsis
5.2.3 Pharyngitis
5.2.4 Methicillin-resistant Staphylococcus aureus (MRSA) Infections
5.2.5 Endocarditis
5.2.6 Meningitis
5.2.7 Other Diseases
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 GlaxoSmithKline Plc
6.1.2 Johnson & Johnson Inc.
6.1.3 Merck & Co. Inc.
6.1.4 Pfizer Inc.
6.1.5 AstraZeneca
6.1.6 Cumberland Pharmaceuticals
6.1.7 Novartis AG
6.1.8 Sanofi SA
6.1.9 Sun Pharmaceutical Industries Ltd.
6.1.10 Cipla Ltd.
6.1.11 Bayer AG
6.1.12 Bristol-Myers Squibb Company
7 MARKET OPPORTUNITIES AND FUTURE TRENDS